Welcome to our dedicated page for Accelerate Diagnostics news (Ticker: AXDX), a resource for investors and traders seeking the latest updates and insights on Accelerate Diagnostics stock.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) delivers innovative solutions for rapid infectious disease testing through its proprietary diagnostic platforms. This page provides investors and healthcare professionals with essential updates on company developments, financial performance, and technological advancements in antimicrobial susceptibility testing.
Access the latest press releases, earnings reports, and regulatory milestones related to AXDX's FDA-cleared systems. Our curated news collection helps stakeholders track progress in combating antibiotic resistance and improving sepsis management through accelerated diagnostics.
Key updates include product launch announcements, partnership developments, and clinical study results for platforms like the Accelerate Pheno® system. All content is verified through primary sources to ensure accuracy and relevance for investment research and clinical decision-making.
Bookmark this page for streamlined access to Accelerate Diagnostics' official communications. Check back regularly for real-time updates on innovations shaping the future of rapid in vitro diagnostics.
Accelerate Diagnostics (AXDX) reported a 20% increase in net sales for Q1 2022, totaling $3.0 million, driven by a 29% rise in recurring revenues. The company ended Q1 with 313 revenue-generating instruments and 76 contracted instruments in progress. However, gross margin decreased to 27% from 36% in Q1 2021 due to rising production costs. The firm's net loss was $14.2 million, translating to $0.21 per share. Despite a cash burn of $13.2 million in the quarter, they improved their balance sheet by raising $4 million from insider financing and reducing debt by $14 million.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced the commercialization of its Accelerate Arc Module and BC kit, aimed at automating microbial identification for positive blood cultures. This system significantly reduces wait times and labor while offering cost savings for healthcare facilities. Registered as an IVD with the FDA, the system is designed for labs using MALDI platforms and requires minimal hands-on time. It allows for faster reporting of identification and antimicrobial susceptibility results, enhancing the efficiency of clinical workflows.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced a conference call to discuss its 2022 first quarter results on May 16, 2022, at 4:30 p.m. ET. The call aims to provide insights into the company's performance during the first quarter. Participants can access the audio webcast via ir.axdx.com and will be available for replay until August 15, 2022. The company focuses on in vitro diagnostics, particularly addressing antimicrobial resistance and sepsis, with systems that expedite identification and susceptibility testing.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) presented new data on the Accelerate Arc Module and BC kit at ECCMID 2022 in Lisbon. The studies revealed that the Arc System enables rapid and accurate microbial identification from positive blood cultures, achieving 94% or greater accuracy compared to conventional MALDI methods. Notably, one study reported 100% agreement in sample results between the Arc and traditional methods. The Arc can identify microorganisms in 90% of blood cultures with minimal hands-on time, significantly improving workflow efficiency for clinical labs.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) launched the Accelerate Arc System on March 28, 2022. This system, designed for labs using MALDI, automates microbial identification from positive blood cultures, significantly reducing wait times and manual processes. The Arc Module integrates inline centrifugal techniques for rapid microbial ID results with just 2-3 minutes of technician hands-on time. This innovation can lower costs by up to 50% compared to existing molecular ID solutions and aims to mitigate contamination issues observed with multi-targeted molecular tests.
Accelerate Diagnostics (AXDX) reported a net sales increase of 6%, reaching $3.3 million in Q4 2021 and a total of $11.8 million for the year, up 5% year-over-year. Despite this growth, the company's net loss widened to $22.8 million in Q4, attributed to non-cash expenses. Gross margin fell to 35% due to pandemic impacts. The company added 16 contracted instruments in Q4, bringing the total to 313 live revenue-generating devices in the U.S. R&D costs decreased slightly to $4.6 million, while total cash and equivalents stood at $63.6 million by year-end.
Accelerate Diagnostics (NASDAQ: AXDX) announced a conference call scheduled for March 8, 2022, at 4:30 p.m. ET to discuss its 2021 fourth quarter and full year financial results. Investors can listen to the call via audio webcast or by phone, with a replay available until March 29, 2022. The company focuses on in vitro diagnostics, providing solutions to tackle antibiotic resistance and sepsis with its FDA-cleared Accelerate Pheno® system, which delivers faster antibiotic susceptibility results.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 10:00 a.m. ET. The conference is exclusive to BTIG clients. Accelerate Diagnostics focuses on in vitro diagnostics, addressing antibiotic resistance and sepsis challenges. Their FDA-cleared Accelerate Pheno® system provides rapid phenotypic antibiotic susceptibility results in approximately 7 hours, enabling timely and optimal antibiotic therapy for patients, significantly faster than traditional methods.
Accelerate Diagnostics (NASDAQ: AXDX) reported preliminary financial results for Q4 and full-year 2021. Key highlights include Q4 expected revenue of $3.3 million, a slight increase from $3.1 million in Q4 2020. Total revenue for 2021 is projected at $11.8 million, compared to $11.2 million in 2020. The company contracted 16 new U.S. Pheno instruments in Q4, totaling 81 instruments in backlog. Gross margin for 2021 is anticipated to be around 35%. Notably, net cash used reached approximately $47 million, leaving a cash balance of $64 million.